CASTLE BIOSCIENCES INC 8-K

What Happened
Castle Biosciences, Inc. (CSTL) announced preliminary performance results for the fourth quarter of 2025 and for the year ended December 31, 2025 via a press release dated January 11, 2026. The company filed a Form 8‑K (Items 2.02 and 7.01) attaching the press release (Exhibit 99.1) and an investor slide presentation (Exhibit 99.2). The filing notes that the information is preliminary and that the press release/slides are not deemed “filed” under Section 18 of the Exchange Act and are not incorporated by reference into other filings.

Key Details

• Filing date / announcement: January 11, 2026 (8‑K filed January 13, 2026; signed by CFO Frank Stokes).
• Items reported: 2.02 (Results of operations and financial condition) and 7.01 (Regulation FD disclosure).
• Exhibits attached: 99.1 = press release with preliminary Q4 2025 and FY 2025 results; 99.2 = slide presentation for investor use.
• Regulatory note: The materials are furnished, not “filed,” and therefore are not subject to Section 18 liability or automatically incorporated into other SEC filings.

Why It Matters
This 8‑K gives investors an early view of Castle’s quarterly and full‑year performance (earnings/revenue/quarterly results) before formal periodic filings (e.g., 10‑K) or a full earnings release. Because the results are described as preliminary and the materials are furnished rather than filed, numbers may be updated or adjusted in subsequent filings or audits. Investors should review the attached press release and slides for the specific performance figures and monitor upcoming SEC filings or company statements for finalized, audited results.